title: Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.
abstract: Glioblastoma multiforme (GBM) is a highly invasive and vascularized aggressive brain tumor. Less than 10% of GBM patients survive >5 years after diagnosis. Angiogenesis plays an important role in GBM growth, and antiangiogenesis-based therapies have shown clinical efficacy for GBM patients. Unfortunately, therapeutic resistance often develops in these patients, suggesting that GBM cells are capable of switching their dependency on one proangiogenic signaling pathway to an alternative one. Therefore, it is important to identify novel angiogenic factors that play essential roles in tumor angiogenesis and GBM progression. Angiopoietins (Ang-1, Ang-2, and Ang-4) are the ligands of the Tie-2 receptor tyrosine kinase (RTK). The roles of Ang-1 and Ang-2 in tumor angiogenesis have been established. However, little is known about how Ang-4 affects tumor angiogenesis and GBM progression and the mechanism underlying its effects. In our current study, we establish that Ang-4 is upregulated in human GBM tissues and cells. We show that, like endothelial cells, human GBM cells express Tie-2 RTK. We first establish that Ang-4 promotes in vivo growth of human GBM cells by promoting tumor angiogenesis and directly activating extracellular signal-regulated kinase 1/2 (Erk1/2) in GBM cells. Our results establish the novel effects of Ang-4 on tumor angiogenesis and GBM progression and suggest that this pro-GBM effect of Ang-4 is mediated by promoting tumor angiogenesis and activating Erk1/2 kinase in GBM cells. Together, our results suggest that the Ang-4-Tie-2 functional axis is an attractive therapeutic target for GBM.
authors.affiliation: Department of Oncological Sciences, Mount Sinai School of Medicine, New York, New York, USA.
authors.forename: Melissa K
authors.initials: MK
authors.lastname: Brunckhorst
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Rong
authors.initials: R
authors.lastname: Lu
authors.forename: Qin
authors.initials: Q
authors.lastname: Yu
mesh_terms: D042682:Angiopoietins / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D001932:Brain Neoplasms / Q000098:blood supply / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D048708:Cell Growth Processes / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000098:blood supply / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D042787:Receptor, TIE-2 / Q000096:biosynthesis; D015854:Up-Regulation
chemical_list: D042682:Angiopoietins; D012333:RNA, Messenger; C118117:angiopoietin 4; D042787:Receptor, TIE-2; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
references.citation: Curr Oncol Rep. 2009 Mar;11(2):111-6
references.pmid: 19216842
references.citation: Circ Res. 2000 Jan 7-21;86(1):24-9
references.pmid: 10625301
references.citation: Nat Struct Mol Biol. 2006 Jun;13(6):524-32
references.pmid: 16732286
references.citation: Nat Rev Cancer. 2008 Aug;8(8):592-603
references.pmid: 18650835
references.citation: Nature. 2000 Sep 14;407(6801):242-8
references.pmid: 11001067
references.citation: J Biol Chem. 2004 Sep 24;279(39):41179-88
references.pmid: 15280392
references.citation: J Biol Chem. 2000 Mar 31;275(13):9102-5
references.pmid: 10734041
references.citation: Oncogene. 2007 Feb 8;26(6):836-50
references.pmid: 16953231
references.citation: Nat Rev Cancer. 2003 Jun;3(6):401-10
references.pmid: 12778130
references.citation: Cell. 1996 Dec 27;87(7):1161-9
references.pmid: 8980223
references.citation: Cancer Res. 2004 Sep 1;64(17):6119-26
references.pmid: 15342395
references.citation: J Clin Oncol. 1999 May;17(5):1474-81
references.pmid: 10334533
references.citation: FASEB J. 2002 Jul;16(9):1126-8
references.pmid: 12039842
references.citation: Br J Cancer. 2000 Nov;83(9):1154-60
references.pmid: 11027428
references.citation: Cancer Res. 2009 Jun 1;69(11):4656-64
references.pmid: 19487284
references.citation: Curr Opin Oncol. 2008 Nov;20(6):652-61
references.pmid: 18841047
references.citation: Neoplasia. 2006 May;8(5):364-72
references.pmid: 16790085
references.citation: FEBS J. 2009 Sep;276(17):4636-43
references.pmid: 19664071
references.citation: Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9355-8
references.pmid: 8415706
references.citation: Cancer Res. 2005 Oct 1;65(19):8679-89
references.pmid: 16204036
references.citation: Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1904-9
references.pmid: 10051567
references.citation: Am J Pathol. 2001 Feb;158(2):563-70
references.pmid: 11159193
references.citation: Cancer Res. 2009 Sep 15;69(18):7243-51
references.pmid: 19738068
references.citation: Cancer Res. 2008 Jul 15;68(14):5733-42
references.pmid: 18632626
references.citation: Cancer Res. 2010 Mar 15;70(6):2455-64
references.pmid: 20197461
references.citation: Science. 1997 Jul 4;277(5322):55-60
references.pmid: 9204896
references.citation: Cell. 1996 Aug 9;86(3):353-64
references.pmid: 8756718
references.citation: J Biol Chem. 2001 Sep 14;276(37):34990-8
references.pmid: 11447223
references.citation: J Clin Invest. 1997 Oct 15;100(8):2072-8
references.pmid: 9329972
references.citation: Oncogene. 2003 Jul 31;22(31):4918-23
references.pmid: 12894235
references.citation: Blood. 2009 Oct 8;114(15):3343-51
references.pmid: 19564638
references.citation: Nat Rev Cancer. 2008 Apr;8(4):309-16
references.pmid: 18337733
references.citation: J Biol Chem. 2005 May 20;280(20):20126-31
references.pmid: 15769741
references.citation: Neurosci Res. 2009 Aug;64(4):348-54
references.pmid: 19379779
references.citation: FASEB J. 2004 Aug;18(11):1200-8
references.pmid: 15284220
references.citation: Nat Med. 1995 Jan;1(1):27-31
references.pmid: 7584949
references.citation: Future Oncol. 2005 Aug;1(4):475-84
references.pmid: 16556024
references.citation: Cell Stem Cell. 2009 Sep 4;5(3):298-309
references.pmid: 19733541
references.citation: FASEB J. 2008 Feb;22(2):488-99
references.pmid: 17873103
references.citation: Mol Cancer Res. 2007 Jul;5(7):655-65
references.pmid: 17634421
references.citation: FEBS J. 2009 Sep;276(17):4653-64
references.pmid: 19664069
references.citation: Neurology. 2008 Mar 4;70(10):779-87
references.pmid: 18316689
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4209-17
references.pmid: 17634550
references.citation: Cancer Res. 2007 May 1;67(9):4254-63
references.pmid: 17483337
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12
references.pmid: 18077431
references.citation: Cancer Cell. 2006 Apr;9(4):287-300
references.pmid: 16616334
references.citation: FASEB J. 2008 Aug;22(8):3010-23
references.pmid: 18502941
references.citation: Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8829-34
references.pmid: 9671764
references.citation: Development. 1993 Nov;119(3):957-68
references.pmid: 8187650
references.citation: Lancet Neurol. 2008 Dec;7(12):1152-60
references.pmid: 19007739